Humanitarian Device Exemption

Profound Medical to Participate in the 2022 Jefferies Global Healthcare Conference

Retrieved on: 
Thursday, June 2, 2022
Company, Conference, Urethra, Food, Webcast, Hyperthermia, CE, Investor, International Medical Corps, Bone, Prostate cancer, Humanitarian Device Exemption, Uterine fibroid, FDA, GLOBE, Health Canada, Rectum, Technology, TSX, NASDAQ, Hematuria, National Medical Products Administration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MRI, Pharmaceutical industry, Medical imaging

TORONTO, June 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Companys business at the 2022 Jefferies Global Healthcare Conference in New York City on Thursday, June 9, 2022 at 4:30 p.m. Eastern Time.

Key Points: 
  • TORONTO, June 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Companys business at the 2022 Jefferies Global Healthcare Conference in New York City on Thursday, June 9, 2022 at 4:30 p.m. Eastern Time.
  • The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.

Profound Medical Annual and Special Meeting of Shareholders Voting Results

Retrieved on: 
Wednesday, May 18, 2022
Company, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Uterine fibroid, Hyperthermia, National Medical Products Administration, Hematuria, MRI, BPH, Bone, CE, PricewaterhouseCoopers, Humanitarian Device Exemption, FDA, Prostate cancer, Technology, Risk, Health Canada, Remuneration, Phrase, Growth, Urethra, Rectum, Pharmaceutical industry, Medical imaging, Profound Pharma

Detailed voting results for all resolutions will be posted under the Companys profile at www.sedar.com .

Key Points: 
  • Detailed voting results for all resolutions will be posted under the Companys profile at www.sedar.com .
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.
  • Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Profound Medical Clarifies Recent Insider Buying

Retrieved on: 
Wednesday, May 18, 2022
Company, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Form 4, Uterine fibroid, Hyperthermia, Hematuria, U.S. Securities and Exchange Commission, Beneficial ownership, Nasdaq, National Medical Products Administration, MRI, NASDAQ, BPH, Bone, CE, TSX, FDA, Humanitarian Device Exemption, Prostate cancer, Technology, The Insider, Risk, Health Canada, Phrase, Growth, Urethra, Rectum, GLOBE, Pharmaceutical industry, Security (finance), Profound Pharma

TORONTO, May 18, 2022 (GLOBE NEWSWIRE) -- In response to investor inquiries regarding insider trading activity, particularly with respect to recent open market stock purchases made by certain of its insiders, Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company) today provided the following clarifications.

Key Points: 
  • TORONTO, May 18, 2022 (GLOBE NEWSWIRE) -- In response to investor inquiries regarding insider trading activity, particularly with respect to recent open market stock purchases made by certain of its insiders, Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company) today provided the following clarifications.
  • This information is being provided solely to assist the Companys shareholders in the present circumstances, and Profound does not intend to issue further press releases regarding insider transactions.
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.

TULSA-PRO® Was Front and Center at AUA2022

Retrieved on: 
Tuesday, May 17, 2022
Department, Physician, Education, Software, University of Texas Southwestern Medical Center, Company, Annual general meeting, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Uterine fibroid, Hyperthermia, American Urological Association, Hematuria, National Medical Products Administration, Susceptibility weighted imaging, Patient, MRI, SWI, NASDAQ, ADC, BPH, Bone, Quality of life, Prostate, AMA, Benign prostatic hyperplasia, CE, Trial of the century, TSX, Humanitarian Device Exemption, DWI, FDA, Urology, Prostate cancer, AUA, Man, University, Technology, Risk, LUTS, Rectum, Diffusion, Health Canada, Plenary session, Turku University, Phrase, Growth, Urethra, Medical Corps (United States Army), GLOBE, Medical imaging, Pharmaceutical industry, Profound Pharma

Of particular note, Kenneth A. Goldberg, M.D., an Assistant Professor in the Department of Urology at UT Southwestern Medical Center, performed a Semi-Live TULSA Procedure during the afternoon Plenary Session on May 13th.

Key Points: 
  • Of particular note, Kenneth A. Goldberg, M.D., an Assistant Professor in the Department of Urology at UT Southwestern Medical Center, performed a Semi-Live TULSA Procedure during the afternoon Plenary Session on May 13th.
  • We are extremely encouraged by the positive feedback we received at this event, which adds to the momentum of Profounds ongoing commercialization strategy for TULSA-PRO.
  • The study reported 6-month improvement in patient quality of life, LUTS, sexual function and uroflowmetry, with all men discontinuing their BPH medication.
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Skyway Capital Markets Advises SPAC on $85 Million Medical Technology Merger

Retrieved on: 
Monday, May 2, 2022
Biotechnology, Finance, Medical Devices, Health, Professional Services, Board, AKI, Cytokine, M&A, FINRA, Health care, Nasdaq, Acute kidney injury, LLC, Monocyte, Roman Catholic Diocese of La Crosse, Death, LMAO, Manifest and latent functions and dysfunctions, Patient, FDA, Inflammation, End organ damage, Environment, Adult, Capital market, Humanitarian Device Exemption, SPAC, Science, SeaStar, Starfish, SCD, Solution, Neutrophil, SIPC, Technology, CEO, Ownership, Growth, Acquisition, Multimedia, Risk management, Financial services

Skyway Capital Markets, LLC (Skyway) is pleased to announce the merger of SeaStar Medical, Inc. (SeaStar Medical), a medical technology company developing extracorporeal therapies to reduce the consequences of excessive inflammation on vital organs, and LMF Acquisition Opportunities, Inc. (Nasdaq: LMAO) (LMAO), a publicly traded special purpose acquisition company.

Key Points: 
  • Skyway Capital Markets, LLC (Skyway) is pleased to announce the merger of SeaStar Medical, Inc. (SeaStar Medical), a medical technology company developing extracorporeal therapies to reduce the consequences of excessive inflammation on vital organs, and LMF Acquisition Opportunities, Inc. (Nasdaq: LMAO) (LMAO), a publicly traded special purpose acquisition company.
  • Skyway Capital Markets LLC served as sole financial and valuation advisor to LMAO in connection with the proposed business combination.
  • Skyway Capital Markets LLC served as sole financial and valuation advisor to LMAO in connection with the proposed business combination.
  • Skyway Capital Markets, LLC is a leading M&A advisor to closely held, founder-owned, family-owned middle-market businesses, and select public companies.

Profound Medical to Participate in the 2022 Bloom Burton & Co. Healthcare Investor Conference

Retrieved on: 
Monday, April 25, 2022
Rectum, Metro Toronto Convention Centre, International Medical Corps, Uterine fibroid, CE, Urethra, Hyperthermia, Phrase, Risk, Regulation of tobacco by the U.S. Food and Drug Administration, NASDAQ, MRI, Food, GLOBE, Humanitarian Device Exemption, Growth, Conference, Technology, Company, Investor, National Medical Products Administration, Prostate cancer, TSX, Health Canada, Bone, FDA, Hematuria, Webcast, BPH, Pharmaceutical industry, Profound Pharma

The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.

Key Points: 
  • The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.
  • Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

SeaStar Medical to Become Publicly Listed on Nasdaq via Business Combination with LMF Acquisition Opportunities, Inc.

Retrieved on: 
Friday, April 22, 2022
Monocyte, 100,000, AKI, Science, SeaStar, GLOBE, Sale, Suite, Patient, Common stock, LinkedIn, Board of directors, End organ damage, Technology, Form, Prospectus, Acute kidney injury, Forward-looking statement, FDA, Acquisition, Securities Act of 1933, COVID-19, Neutrophil, Adoption, U.S. Securities and Exchange Commission, Adult, Annual report, Private Securities Litigation Reform Act, Chief executive officer, Humanitarian Device Exemption, Solution, Tripura Merger Agreement, Cytokine, SCD, Board, XV, Twitter, Failure, Nasdaq, Section 10 of the Canadian Charter of Rights and Freedoms, SEC, Industry, PIPE, Death, Inflammation, Person, Shareholder, Registration statement, Register, Critical care, Manifest and latent functions and dysfunctions, Risk, LMAO, Hospital, Security (finance), Pharmaceutical industry, Risk management

This is a tremendous opportunity to transform patient treatment, said Eric Schlorff, President and Chief Executive Office of SeaStar Medical.

Key Points: 
  • This is a tremendous opportunity to transform patient treatment, said Eric Schlorff, President and Chief Executive Office of SeaStar Medical.
  • The combined company will be known as SeaStar Medical Holding Corporation and will operate under the same management team as SeaStar Medical, which is led by Mr. Schlorff.
  • As part of the transaction, all SeaStar Medical shares owned by SeaStar Medicals existing equity holders will be converted into Class A Common Stock of SeaStar Medical Holding Corporation.
  • Maxim Group LLC served as sole financial advisor to SeaStar Medical in connection with the proposed business combination.

Profound Medical to Release First Quarter 2022 Financial Results on May 9 – Conference Call to Follow

Retrieved on: 
Monday, April 18, 2022
Rectum, Uterine fibroid, CE, Urethra, Hyperthermia, Phrase, Risk, Regulation of tobacco by the U.S. Food and Drug Administration, MRI, Food, Humanitarian Device Exemption, Growth, Technology, Company, Investor, National Medical Products Administration, Prostate cancer, Health Canada, Bone, FDA, Hematuria, Webcast, BPH, Pharmaceutical industry, Medical imaging, Profound Pharma

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Key Points: 
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.
  • TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (FDA).
  • Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Profound Medical to Participate in March Investor Conferences

Retrieved on: 
Wednesday, March 2, 2022
Phrase, Regulation of tobacco by the U.S. Food and Drug Administration, TSX, Health Canada, National Medical Products Administration, Investor, Risk, Food, BPH, Rectum, FDA, Growth, Bone, Hematuria, Uterine fibroid, Company, International Medical Corps, Conference, Humanitarian Device Exemption, Prostate cancer, Urethra, Webcast, CE, Technology, Hyperthermia, MRI, GLOBE, NASDAQ, Pharmaceutical industry, Profound Pharma

TORONTO, March 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in two investor conferences in March.

Key Points: 
  • TORONTO, March 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in two investor conferences in March.
  • 42nd Annual Cowen Health Care Conference: Profound is scheduled to present virtually on Monday, March 7, 2022 at 10:30 a.m.
  • Raymond James 43rd Annual Institutional Investors Conference: Profound is scheduled to present on Wednesday, March 9, 2022 at 9:50 a.m.
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound Medical’s TULSA-PRO® Now Compatible with GE Healthcare’s 3T MRI Scanners

Retrieved on: 
Tuesday, March 1, 2022
Urethra, GLOBE, TSX, Prostate cancer, Magnetic resonance, International Medical Corps, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cone Health Women's Hospital, Phrase, Risk, Growth, National Medical Products Administration, GE Healthcare, NASDAQ, Hospital, Man, General manager, MRI, Company, Disease, Rectum, Bone, Prostate, Food, BPH, Hematuria, Hyperthermia, Health Canada, FDA, Technology, Humanitarian Device Exemption, Uterine fibroid, Mortality, CE, GE, Medical imaging, Pharmaceutical industry, Brigham, Profound Pharma

Profound subsequently signed the first site agreement for a TULSA-PRO system interfaced with a GE scanner with Bostons renowned Brigham and Women's Hospital.

Key Points: 
  • Profound subsequently signed the first site agreement for a TULSA-PRO system interfaced with a GE scanner with Bostons renowned Brigham and Women's Hospital.
  • For decades, GE Healthcare has proudly equipped clinicians with advanced MRI technologies to visualize and diagnose prostate cancer.
  • Now, we are proud to enable access to a new tool to help clinicians treat this disease under precise MRI guidance: Profounds TULSA-PRO.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.